[1]
|
Effects of sodium‐glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretion
Endocrinology, Diabetes & Metabolism,
2019
DOI:10.1002/edm2.44
|
|
|
[2]
|
Effects of sodium-glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretion
Endocrinology, Diabetes & Metabolism,
2018
DOI:10.1002/edm2.44
|
|
|
[3]
|
Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study
Expert Opinion on Pharmacotherapy,
2017
DOI:10.1080/14656566.2017.1293652
|
|
|
[4]
|
The potential effect of ultra-long insulin degludec on glycemic variability
Diabetes Research and Clinical Practice,
2017
DOI:10.1016/j.diabres.2017.06.003
|
|
|
[5]
|
Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy
Journal of Diabetes Investigation,
2015
DOI:10.1111/jdi.12314
|
|
|
[6]
|
Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan
Journal of Diabetes Investigation,
2015
DOI:10.1111/jdi.12348
|
|
|
[7]
|
An Open-label Longitudinal Study on the Efficacy of Switching from Insulin Glargine or Detemir to Degludec in Type 2 Diabetes Mellitus
Internal Medicine,
2015
DOI:10.2169/internalmedicine.54.3993
|
|
|
[8]
|
Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first‐year report from Japan
Journal of Diabetes Investigation,
2015
DOI:10.1111/jdi.12348
|
|
|
[9]
|
Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide‐analog administration to intensive insulin therapy
Journal of Diabetes Investigation,
2015
DOI:10.1111/jdi.12314
|
|
|
[10]
|
Medium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
Drugs in R&D,
2014
DOI:10.1007/s40268-014-0048-6
|
|
|